Dose-Intense Chemotherapy Shown to Improve Outcomes in Patients with Breast Cancer

JHOP - December 2017 Vol 7, No 4 - Breast Cancer

Dose-intense chemotherapy can be accomplished by either shortening the intervals between chemotherapy cycles or by administering the agents sequentially instead of at the same time. The sequential approach allows higher doses of the individual drugs to be used in each cycle while keeping the side effects manageable.

As published in the Annals of Oncology, German researchers performed a 10-year follow-up analysis of a trial that enrolled 1284 patients with high-risk breast cancer, defined as involvement of ≥4 axillary lymph nodes.1 Patients in the study were randomly assigned to either standard epirubicin (Ellence)/cyclophosphamide (Cytoxan, Endoxan, Neosar, Procytox, Revimmune, Cycloblastin) followed by paclitaxel (Taxol, Abraxane)  every 3 weeks, or a dose-dense regimen consisting of 3 courses each of epirubicin 150 mg/m2, paclitaxel 225 mg/m2, and cyclophosphamide 2500 mg/m2, every 2 weeks.

After 10 years, they found survival without a breast event improved from 47% in the standard-treatment group to 56% in the dose-dense group. Furthermore, 69% of the dose-dense group was still alive at 10 years compared with 59% in those receiving the standard regimen. Patients with more positive axillary lymph nodes had the greatest survival benefit from the dose-dense regimen.

A second analysis, this one presented at the 2017 San Antonio Breast Cancer Symposium, looked at data from 25 studies that included more than 34,000 patients with early breast cancer.2 The studies employed 3 different dose-intense strategies:

  • Giving treatment every 2 weeks instead of every 3 weeks
  • Giving drugs sequentially over 3 weeks instead of concurrently
  • A combination of the 2 approaches.

In each instance, the dose-intense regimen was better than standard regimens on the outcomes of disease recurrence and cancer-related death.

The rate of recurrence after 10 years was reduced by 17% and the risk for breast cancer death was reduced by 14% when chemotherapy was given every 2 weeks instead of every 3 weeks.          

The study’s lead investigator, Richard Gray, MSc, Professor of Medical Statistics in the Nuffield Department of Population Health at the University of Oxford, UK, commented that the 14% reduction in breast cancer death is impressive given that standard chemotherapy regimens have already reduced breast cancer death by about one-third. “These increments really make a difference to breast cancer survivors just by identifying a way of improving what we’re doing already,” he said.

In the trials comparing sequential with concurrent therapy, the relative risk of recurrence was 13% lower and the relative risk of breast cancer death was 11% lower in the sequential arms.

Finally, in the studies combining the 2 strategies, the dose-intense regimens reduced the risk of recurrence by 18% and the risk of breast cancer death by an identical 18%.

“This was quite remarkable how consistent all these different approaches were, showing fewer recurrence and fewer breast cancer mortalities,” he said. In pooling all 25 dose-intensification trials, Gray’s team found a 15% relative reduction in recurrence and a 13% reduction in breast cancer death with dose intensification.

The improvements on these end points were similar in patients with estrogen receptor–positive or estrogen receptor–negative disease, and did not differ by any other tumor or patient characteristic.

He noted that the dose-intensification regimens may cause anemia and low white blood cell counts and, therefore, may require appropriate supportive care to increase blood counts.

References
1. Möbus V, Jackisch C, Lück HJ, et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol. 2018;29:178-185.
2. Gray R, Bradley R, Braybrooke J, et al. Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: an EBCTCG meta-analysis of 21,000 women in 16 randomised trials. Presented at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017. Abstract GS1-01.

Related Items
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape
The Pharmacist and Patients With HER2-Positive or HER2-Low Metastatic Breast Cancer: Navigating the Treatment Landscape published on January 11, 2024 in Breast Cancer
Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Emily M. Beard, RN, BSN, OCN, CBCN, Abbey J. Kaler, MS, APRN, FNP-C, Mohammed A. Jaloudi, MD
Best Practices in Ovarian Function Suppression in Breast Cancer published on December 21, 2023 in Breast Cancer
Enhertu Received Regular FDA Approval for Patients with Unresectable or Metastatic Breast Cancer
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in FDA Oncology Update, Breast Cancer
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Lynparza Receives FDA Approval for Adjuvant Treatment of High-Risk Early Breast Cancer with BRCA Mutation
JHOP - April 2022 Vol 12, No 2 published on May 3, 2022 in FDA Oncology Update, Breast Cancer
Evaluating Adverse Events in Patients with Breast Cancer and HIV Infection Receiving Concomitant Antiretroviral Therapy and Chemotherapy with Curative Intent
Donyika Joseph, PharmD, BCOP, Farnaz Foolad, PharmD, BCPS, Neelam K. Patel, PharmD, BCOP, Meghan Karuturi, MD, MSc, Jaime Kaushik, PharmD, BCOP
JHOP - April 2022 Vol 12, No 2 published on May 2, 2022 in Original Article, Adverse Events, Breast Cancer, Infections
Advances in Breast Cancer Treatments: Are We Extending Patients’ Survival?
Meg Barbor, MPH
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in HOPA Highlights, Breast Cancer
Development and Implementation of a Pharmacist-Led Virtual Clinic Improve the Management of Patients with Metastatic Breast Cancer Receiving CDK4/6 Inhibitors
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Time to Treatment Initiation and Outcomes for Patients with Nonmetastatic Breast Cancer Before and During the COVID-19 Pandemic at Community Cancer Centers
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in HOPA Abstracts, Breast Cancer
Spontaneous Tumor Lysis Syndrome in a Patient with Stage IV HER2-Positive Breast Cancer: Case Report
Blake T. Robbins, PharmD, MBA , Alexander M. Kreimer, PharmD, BCPS , Reema A. Patel, MD, Allison R. Butts, PharmD, BCOP
JHOP - February 2022 Vol 12, No 1 published on March 1, 2022 in Case Reports, Tumor Lysis Syndrome, Breast Cancer
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: